MDXG
MiMedx Group·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MDXG
Mimedx Group, Inc.
A transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare
1775 West Oak Commons Court
, NE
, Marietta
, GA 30062
--
MiMedx Group, Inc., is incorporated in Florida. The company is a pioneer and leader in placental biologics focused on helping humans heal. With more than a decade of helping clinicians manage chronic and difficult-to-heal wounds, MIMEDX is committed to providing a leading product portfolio for wound care, burns and surgery applications in healthcare. The company's vision is to become the world's leading provider of rehabilitation solutions to restore quality of life through relentless innovation. With deep expertise, leading peer-reviewed data, and an extensive library of additional scientific and real-world evidence in the field of placental biologics, MIMEDX develops and distributes placental tissue allografts, which are manufactured using proprietary, patent-protected processes for multiple sectors of healthcare.
Earnings Call
Q1/2025
Estimate EPS0.05
Actual EPS0.06
Estimate Revenue86.32M
Actual Revenue88.20M
Navigating Contradictions: Insights from MIMEDX's Q1 2025 Earnings Call on Margins, Market Dynamics, and HELIOGEN's Future
May 07,2025 02:38
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.05
Actual EPS0.1
Estimate Revenue90.79M
Actual Revenue98.61M
MiMedx's Q2 2025 Earnings Call: Contradictions on Market Share, Regulations, and Growth Prospects
Jul 30,2025 11:10
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MDXG has released its 2025 Q3 earnings. EPS was reported at 0.15, versus the expected 0.08, beating expectations. The chart below visualizes how MDXG has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MDXG has released its 2025 Q3 earnings report, with revenue of 113.72M, reflecting a YoY change of 35.30%, and net profit of 16.75M, showing a YoY change of 106.89%. The Sankey diagram below clearly presents MDXG's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
